Attribute level | Patients (n = 142) Mean (SD) | Physicians (n = 127) Mean (SD) |
Increase in 3-year recurrence-free survival 4% 8% 12% |
−43.0 (38) 8.9 (24) 34.1 (35) |
−33.2 (43) −2.3 (19) 35.5 (40) |
10-year survival benefit in metastatic patients No proven benefit 10% remain alive 21% remain alive |
−77.8 (67) 6.8 (36) 71.0 (84) |
−116.4 (78) −4.1 (31) 120.5 (70) |
Dosing regimen Self-injection under skin 1 time per week for 5 years |
−4.50 (43) |
3.4 (25) |
IV infusion at clinic 1 time every 3 week for 4 times then 1 time every 3 months for 3 years | 15.5 (42) | −1.8 (28) |
IV infusion at clinic 5 days a week for 1 month then self-injection under the skin 3 times per week for 1 year | −11.0 (40) | −1.6 (33) |
Risk of moderate to severe fatigue 32% 60% 95% |
45.8 (36) 12.4 (29) −58.2 (30) |
35.4 (38) 12.5 (25) −47.9 (38) |
Risk of moderate to severe diarrhea 1% 27% 41% |
30.1 (31) −3.2 (22) −26.8 (30) |
18.7 (32) 0.03 (30) −18.8 (37) |
Risk of moderate to severe depression 1% 40% 59% |
39.4 (31) −8.2 (21) −31.2 (31) |
28.7 (27) −10.6 (22) −18.2 (33) |
Risk of hypophysitis 0% 5% 18% |
9.1 (21) 11.2 (20) −20.3 (25) |
10.5 (26) −1.7 (24) −8.8 (32) |
None | −90.7 (294) | −97.2 (212) |